olaparib
astrazeneca,merck
['gyn', 'brca-p', 'ovarian', 'brca', 'olaparib']
after 7 years of follow-up, maintenance therapy with olaparib for 2 years reduced risk for death by 45% vs placebo in patients with newly diagnosed advanced, brca-positive ovarian cancer. #esmo2022 #gyncsm #ovariancancer | 
Oncology news and insights from leading researchers and cancer centers.